| Prev Close | 48.68 |
| Open | 48.00 |
| Day Low/High | 47.50 / 48.21 |
| 52 Wk Low/High | 35.77 / 58.37 |
| Volume | 1.30M |
| Avg Volume | 1.50M |
| Exchange | NYSE |
| Shares Outstanding | 2.01B |
| Market Cap | 123.18B |
| EPS | 2.40 |
| Div & Yield | 0.91 (1.87%) |
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
New Findings by Novo Nordisk Provide Insights into Holistic Diabetes Care Management for Patients and Their Physicians
